59.40

5.86% 3.29

After Hours: 59.50 0.10 +0.17%

Exact Sciences Corp (EXAS)

Overview News Price History Option Chain Financials Discussions Forecast

Exact Sciences Corp stock is traded at $59.40, with a volume of 2.80M. It is up +5.86% in the last 24 hours and up +12.71% over the past month. Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Previous Close:

$56.11

Open:

$56.04

24h Volume:

2.80M

Relative Volume:

1.16

Market Cap:

$10.99B

Revenue:

$2.69B

Net Income/Loss:

$-214.04M

P/E Ratio:

-37.46

EPS:

-1.5857

Net Cash Flow:

$98.43M

1W Performance:

-3.02%

1M Performance:

+12.71%

6M Performance:

+35.00%

1Y Performance:

-11.74%

1-Day Range:

$55.98

$59.70

1-Week Range:

$55.65

$62.15

52-Week Range:

$40.62

$79.62

Exact Sciences Corp Stock (EXAS) Company Profile

Name

Exact Sciences Corp

Sector

Healthcare (1176)

Industry

Diagnostics & Research (57)

Phone

608-284-5700

Address

5505 ENDEAVOR LANE, MADISON, WI

Employee

6,600

Twitter

@exactsciences

Next Earnings Date

2024-11-05

Latest SEC Filings

EXAS's Discussions on Twitter

Compare EXAS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXAS Exact Sciences Corp	59.40	10.99B	2.69B	-214.04M	98.43M	-1.17
TMO Thermo Fisher Scientific Inc	524.05	200.45B	42.37B	6.14B	7.78B	15.95
DHR Danaher Corp	228.55	165.08B	23.74B	3.89B	4.98B	5.24
A Agilent Technologies Inc	134.51	38.36B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	197.27	35.80B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	412.26	33.76B	3.84B	866.24M	792.60M	10.37

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Buy
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy
May-05-23	Initiated	UBS	Neutral
Mar-09-23	Upgrade	Citigroup	Neutral → Buy
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform
Jul-29-21	Reiterated	BTIG Research	Buy
Jul-29-21	Reiterated	Canaccord Genuity	Buy
Jul-29-21	Reiterated	Oppenheimer	Outperform
Jul-29-21	Reiterated	Stifel	Buy
Jun-15-21	Initiated	Raymond James	Strong Buy
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Equal Weight
Jan-28-21	Initiated	Truist	Buy
Oct-29-20	Downgrade	UBS	Buy → Neutral
Oct-28-20	Downgrade	Citigroup	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Apr-02-20	Initiated	Evercore ISI	Outperform
Jan-10-20	Resumed	BTIG Research	Buy
Jan-07-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Dougherty & Company	Buy
Nov-15-19	Initiated	Stifel	Buy
Oct-17-19	Reiterated	BofA/Merrill	Buy
Oct-01-19	Resumed	Craig Hallum	Buy
Sep-26-19	Initiated	Oppenheimer	Outperform
Feb-26-19	Upgrade	Goldman	Neutral → Buy
Oct-09-18	Initiated	UBS	Buy
Sep-05-18	Resumed	The Benchmark Company	Hold
Aug-13-18	Reiterated	Canaccord Genuity	Buy
Apr-03-18	Upgrade	BTIG Research	Neutral → Buy
Jan-29-18	Initiated	Goldman	Neutral
Jan-08-18	Reiterated	The Benchmark Company	Buy
Nov-13-17	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-01-17	Downgrade	BTIG Research	Buy → Neutral

View All

Exact Sciences Corp Stock (EXAS) Latest News

Dec 16, 2024

Tidal Investments LLC Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Dec 16, 2024

Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Toronto Dominion Bank - MarketBeat

Dec 16, 2024

Dec 15, 2024

Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Public Employees Retirement System of Ohio - MarketBeat

Dec 15, 2024

Dec 14, 2024

Exact Sciences (NASDAQ:EXAS) Price Target Lowered to $72.00 at Bank of America - MarketBeat

Dec 14, 2024

Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 14, 2024

Dec 10, 2024

Groupama Asset Managment Acquires Shares of 1,204,952 Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Dec 10, 2024

Dec 09, 2024

Exact Sciences Corp reports results for the quarter ended in September 30Earnings Summary - XM

Dec 09, 2024

AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates - Yahoo Finance

Dec 09, 2024

Dec 08, 2024

Pier Capital LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Dec 08, 2024

Dec 06, 2024

Soros Fund Management LLC Boosts Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Dec 06, 2024

Lil Jon Remixes Iconic ‘Get Low’ Hit To Promote Colon Cancer Screenings - Black Enterprise

Dec 06, 2024

Dec 05, 2024

Polar Asset Management Partners Inc. Acquires 45,800 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Dec 05, 2024

Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Cerity Partners LLC - MarketBeat

Dec 05, 2024

Dec 04, 2024